KDA Group Valuation
Is O1M undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of O1M when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate O1M's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate O1M's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for O1M?
Key metric: As O1M barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is O1M's PB Ratio? | |
|---|---|
| PB Ratio | 2.7x |
| Book | CA$14.40m |
| Market Cap | CA$39.49m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 189.4x |
| Enterprise Value/EBITDA | -10.6x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does O1M's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.4x | ||
V3V VITA 34 | 3.2x | 74.8% | €74.6m |
NN6 NanoRepro | 0.5x | n/a | €20.0m |
JTH Gesundheitswelt Chiemgau | 0.6x | n/a | €23.8m |
SYAB SYNLAB | 1.1x | -11.4% | €2.5b |
O1M KDA Group | 2.7x | n/a | €39.5m |
Price-To-Book vs Peers: O1M is expensive based on its Price-To-Book Ratio (2.7x) compared to the peer average (1.4x).
Price to Book Ratio vs Industry
How does O1M's PB Ratio compare vs other companies in the DE Healthcare Industry?
| 1 Company | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
HT6 Learning 2 Sleep L2S | 0.03x | n/a | US$93.28k |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Book vs Industry: O1M is expensive based on its Price-To-Book Ratio (2.7x) compared to the European Healthcare industry average (1.5x).
Price to Book Ratio vs Fair Ratio
What is O1M's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 2.7x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate O1M's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Universal Health Services
US$13.1b
Through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities.
UHS
US$186.00
7D
-5.6%
1Y
50.0%
Shandong Weigao Group Medical Polymer
HK$20.7b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.53
7D
-6.2%
1Y
-37.3%
CVS Health
US$70.5b
Provides health solutions in the United States.
CVS
US$53.28
7D
3.9%
1Y
-14.3%